Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Sells 375,815 Shares

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $9.30, for a total value of $3,495,079.50. Following the completion of the transaction, the insider directly owned 4,811,341 shares of the company’s stock, valued at $44,745,471.30. This represents a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total transaction of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total transaction of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total transaction of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total value of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.04, for a total value of $1,250,260.20.
• On Thursday, July 30th, L1 Capital Pty Ltd sold 558,633 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.20, for a total value of $4,580,790.60.
• On Monday, July 27th, L1 Capital Pty Ltd sold 232,817 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.19, for a total value of $1,906,771.23.
• On Tuesday, July 28th, L1 Capital Pty Ltd sold 208,731 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.09, for a total value of $1,688,633.79.

Anteris Technologies Global Trading Down 3.3%

Shares of NASDAQ:AVR opened at $8.87 on Thursday. The stock has a market capitalization of $863.42 million, a P/E ratio of -4.55 and a beta of 1.78. Anteris Technologies Global Corp. has a 1-year low of $3.30 and a 1-year high of $11.06. The business has a 50-day moving average price of $9.15 and a two-hundred day moving average price of $7.35.

Anteris Technologies Global (NASDAQ:AVR) last released its earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 110.36%. The business had revenue of $1.01 million for the quarter, compared to analyst estimates of $1.50 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. As a group, equities analysts predict that Anteris Technologies Global Corp. will post -1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Barclays raised their price objective on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Friday, May 29th. Finally, Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Anteris Technologies Global in the 1st quarter worth $32,000. Geode Capital Management LLC boosted its holdings in shares of Anteris Technologies Global by 154.3% in the 2nd quarter. Geode Capital Management LLC now owns 420,427 shares of the company’s stock valued at $1,593,000 after buying an additional 255,088 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Anteris Technologies Global by 9,958.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,068,328 shares of the company’s stock valued at $4,049,000 after buying an additional 1,057,707 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Anteris Technologies Global by 1.8% in the second quarter. Nantahala Capital Management LLC now owns 1,693,666 shares of the company’s stock valued at $6,419,000 after buying an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Anteris Technologies Global by 85.1% in the third quarter. Vanguard Group Inc. now owns 745,560 shares of the company’s stock valued at $3,355,000 after buying an additional 342,711 shares in the last quarter.

Key Stories Impacting Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Q2 loss narrowed and sales increased: Anteris reported a second-quarter 2026 loss of $0.30 per share, an improvement from the $0.58 loss recorded a year earlier. Net sales rose to $1.01 million, although the figure remained below the $1.50 million analyst estimate. Anteris Technologies Q2 Loss Narrows, Net Sales Rise
• Positive Sentiment: Medicare reimbursement eligibility supports the clinical program: The company said eligible U.S. sites in its global pivotal PARADIGM trial can receive Medicare reimbursement under a Centers for Medicare & Medicaid Services national coverage policy. This could improve trial execution and reduce financial barriers to participation. Anteris Technologies Announces Results for the Second Quarter of 2026
• Neutral Sentiment: Development-stage profile remains central to the outlook: Anteris continues investing heavily in medical-device development, reflected in its extremely negative net margin and negative return on equity. Investors are likely focused on clinical milestones, commercialization prospects and future funding needs rather than near-term profitability.
• Negative Sentiment: Quarterly results missed expectations: The $0.30-per-share loss was wider than the consensus estimate of $0.21, while revenue also fell short of expectations. The earnings miss can weigh on the stock despite year-over-year improvement. Anteris Technologies Global earnings report
• Negative Sentiment: Major shareholder continues reducing its position: L1 Capital Pty Ltd disclosed sales of 375,815 shares on August 11 and 251,844 shares on August 10, following earlier sales including 174,721 shares on August 6. The repeated selling, totaling more than 800,000 shares across these disclosures, creates additional supply and may signal reduced conviction or portfolio rebalancing. SEC filing on L1 Capital share sales

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.